We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+5.06%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$11.8B
AUM Growth
+$261M
Cap. Flow
+$368M
Cap. Flow %
3.12%
Top 10 Hldgs %
80.71%
Holding
127
New
5
Increased
21
Reduced
20
Closed
13

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$268M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$210M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$46.6M
4
HRTX icon
Heron Therapeutics
HRTX
+$44.6M
5
ACGN
Aceragen Inc
ACGN
+$41M

Top Sells

Rank Stock Value
1
ABLX
Ablynx NV
ABLX
+$98.3M
2
RXDX
Ignyta, Inc.
RXDX
+$37M
3
IMGN
Immunogen Inc
IMGN
+$16.4M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$10.8M
5
ANAB icon
AnaptysBio
ANAB
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 93.85%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRE icon
51
Spyre Therapeutics
SYRE
$8.5B
$11.3M 0.1%
45,515
– –
ACHN
52
DELISTED
Achillion Pharmaceuticals
ACHN
$10.6M 0.09%
2,856,637
– –
CPRX
53
DELISTED
Catalyst Pharmaceutical
CPRX
$10.5M 0.09%
4,381,072
-1,471,081
-25% -$4.89M
VNDA icon
54
Vanda Pharmaceuticals
VNDA
$304M
$10.1M 0.09%
600,354
+176,470
+42% +$2.95M
ASMB icon
55
Assembly Biosciences
ASMB
$498M
$9.52M 0.08%
16,149
-10,745
-40% -$6.66M
ANAB icon
56
AnaptysBio
ANAB
$1.54B
$9.48M 0.08%
91,086
-90,300
-50% -$10.2M
MGNX icon
57
MacroGenics
MGNX
$233M
$9.15M 0.08%
363,676
– –
CBIO
58
Crescent Biopharma
CBIO
$546M
$9.14M 0.08%
5,633
– –
RIGL icon
59
Rigel Pharmaceuticals
RIGL
$723M
$8.92M 0.08%
251,888
– –
FOMX
60
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$8.2M 0.07%
1,598,991
-867,711
-35% -$5.22M
GNMX
61
DELISTED
Aevi Genomic Medicine Inc
GNMX
$8.15M 0.07%
4,055,142
– –
ALBO
62
DELISTED
Albireo Pharma Inc
ALBO
$8.14M 0.07%
250,000
+50,000
+25% +$1.68M
SYRS
63
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$7.46M 0.06%
57,484
– –
XLRN
64
DELISTED
Acceleron Pharma
XLRN
$6.41M 0.05%
163,900
– –
GTHX
65
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$6.28M 0.05%
+169,492
New +$4.52M
ALKS icon
66
Alkermes
ALKS
$8.11B
$5.81M 0.05%
100,251
-50,000
-33% -$2.93M
IFRX icon
67
InflaRx
IFRX
$243M
$5.77M 0.05%
200,000
– –
FSTX
68
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$5.74M 0.05%
93,286
– –
CCXI
69
DELISTED
ChemoCentryx, Inc.
CCXI
$5.63M 0.05%
414,029
+364,965
+744% +$3.77M
MNTA
70
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$5.6M 0.05%
+308,500
New +$5.14M
NBRV
71
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$4.72M 0.04%
3,753
– –
LJPC
72
DELISTED
La Jolla Pharmaceutical Company
LJPC
$4.61M 0.04%
154,675
– –
SLDB icon
73
Solid Biosciences
SLDB
$792M
$4.41M 0.04%
+39,192
New +$13.2M
STML
74
DELISTED
Stemline Therapeutics, Inc.
STML
$4.4M 0.04%
287,827
-345,670
-55% -$5.39M
NVAX icon
75
Novavax
NVAX
$1.21B
$4.2M 0.04%
100,000
– –
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2018 Portfolio in Review

As of Q1 2018, Baker Bros. Advisors held 127 positions worth $11.8B, up 2.3% from $11.5B the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Baker Bros. Advisors deployed $368M of net new capital in Q1 2018, opening 5 new positions and adding to 21 existing holdings. Its largest new stake was VYNE Therapeutics: 194 shares worth $26.3M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Ablynx NV, an estimated $98.3M trimmed.

  • Baker Bros. Advisors's largest Q1 2018 buy was VYNE Therapeutics: 194 shares worth $26.3M.
  • Baker Bros. Advisors added most to BeOne Medicines Ltd in Q1 2018, an estimated $268M increase.
  • Baker Bros. Advisors's biggest Q1 2018 reduction was Ablynx NV, cutting an estimated $98.3M.
  • Baker Bros. Advisors fully exited Ignyta, Inc. in Q1 2018, selling an estimated $37M.
  • Baker Bros. Advisors's ten largest holdings make up 81% of its $11.8B portfolio in Q1 2018.
  • Baker Bros. Advisors opened 5 new positions and closed 13 in Q1 2018.
  • Baker Bros. Advisors's portfolio value rose 2.3% quarter-over-quarter to $11.8B.

Based on Baker Bros. Advisors's 13F filing for Q1 2018, filed 15 May 2018.